Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21274783 | 0.89 | MAOB (0.51) | SRD5A2POLBDHODHLTA4H | |
| SCHEMBL31522070 | 0.87 | SOS1 (0.49) | SRD5A2POLB | |
| SCHEMBL28260959 | 0.86 | PARP10 (0.56) | SRD5A2POLBAKR1C3KMT2APARP10 | |
| SCHEMBL922752 | 0.86 | POLB (0.57) | SRD5A2POLBAKR1C3DHODHCYP2C9 | |
| SCHEMBL16506909 | 0.85 | LPAR1 (0.57) | POLBPARP10 | |
| Hydrochloric Acid SCHEMBL921227 | 0.84 | POLB (0.55) | SRD5A2POLBAKR1C3DHODHCYP2C9 | |
| SCHEMBL23386692 | 0.83 | XDH (0.51) | SRD5A2POLBAKR1C3KMT2A | |
| SCHEMBL30287662 | 0.83 | POLB (0.77) | SRD5A2POLBAKR1C3CYP2C9CYP2C19 | |
| SCHEMBL522949 | 0.83 | POLB (0.77) | SRD5A2POLBAKR1C3CYP2C9CYP2C19 | |
| SCHEMBL28576596 | 0.81 | POLB (0.75) | SRD5A2POLBAKR1C3CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121591743-A | Li Zalu preparation method of tenib and intermediate thereof | 山东特珐曼药业有限公司 | 2026-03-03 | — | — | CN | disclosed |
| CN-119119189-A | Polypeptides having MMP2 inhibitory effect | 大正制药株式会社 | 2024-12-13 | — | — | CN | disclosed |
| CN-114450294-B | Polypeptides having MMP2 inhibitory effect | 大正制药株式会社 | 2024-11-26 | — | — | CN | disclosed |
| US-20240199692-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-20 | — | — | US | disclosed |
| CN-115894497-A | Imidazopyrimidine compounds, and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-4056581-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | Taisho Pharmaceutical Co., Ltd. (JP) | 2022-09-14 | — | — | EP | disclosed |
| CN-104163772-A | Substituted diaryl ester compound, and preparation method and application thereof | UNIV XIAMEN | 2014-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199692-A1 | POLYPEPTIDE HAVING MMP2-INHIBITORY EFFECT | MMP2, MMP26, MMP25 | SRD5A2 2738/4885POLB 2383/4885AKR1C3 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.